Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 6/2022

22.11.2021 | Editorial

Dual Anti-platelet Therapy After Transcatheter Aortic Valve Implantation: Double Trouble?

verfasst von: Faisal Rahman, Waleed T. Kayani, Yochai Birnbaum, Hani Jneid

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Excerpt

Transcatheter aortic valve implantation (TAVI) has emerged over the last decade as a viable treatment option for patients with severe symptomatic aortic stenosis (AS) across all risk strata with TAVI procedural volumes increasing significantly over time and currently exceeding surgical aortic valve replacement surgery volumes in the USA [1]. The most common complication associated with TAVI is vascular bleeding, which portends a higher mortality risk [2]. Bleeding risk is related to a combination of patient-related factors and pharmacotherapies. Therefore, it is increasingly important to choose, in a shared-decision making process with the patient, the appropriate antithrombotic therapy post-TAVI that will balance bleeding risk with thromboembolic events and long-term valve function to give the best outcomes for patients. This is an important area of consideration as subclinical leaflet thrombosis appears to be more common after TAVI than surgical valve replacement (up to 10–15% in some series) and is associated with increased risk of cerebrovascular events [3, 4]. …
Literatur
1.
Zurück zum Zitat Carroll JD, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76(21):2492–516.CrossRefPubMed Carroll JD, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76(21):2492–516.CrossRefPubMed
2.
Zurück zum Zitat Zahid S, et al. Trends, predictors, and outcomes of major bleeding after transcatheter aortic valve implantation, from national inpatient sample (2011–2018). Expert Rev Cardiovasc Ther. 2021;19(6):557–63.CrossRefPubMed Zahid S, et al. Trends, predictors, and outcomes of major bleeding after transcatheter aortic valve implantation, from national inpatient sample (2011–2018). Expert Rev Cardiovasc Ther. 2021;19(6):557–63.CrossRefPubMed
3.
Zurück zum Zitat Chakravarty T, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383–92.CrossRefPubMed Chakravarty T, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383–92.CrossRefPubMed
4.
Zurück zum Zitat Makkar RR, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015–24.CrossRefPubMed Makkar RR, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015–24.CrossRefPubMed
5.
Zurück zum Zitat Leon MB, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–607.CrossRefPubMed Leon MB, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–607.CrossRefPubMed
6.
Zurück zum Zitat Rodes-Cabau J, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10(13):1357–65.CrossRefPubMed Rodes-Cabau J, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10(13):1357–65.CrossRefPubMed
7.
Zurück zum Zitat Brouwer J, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383(15):1447–57.CrossRefPubMed Brouwer J, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383(15):1447–57.CrossRefPubMed
8.
Zurück zum Zitat Dangas GD, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120–9.CrossRefPubMed Dangas GD, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120–9.CrossRefPubMed
9.
Zurück zum Zitat Collet JP, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J. 2018;200:44–50.CrossRefPubMed Collet JP, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J. 2018;200:44–50.CrossRefPubMed
11.
Zurück zum Zitat Lin X. Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve replacement: a systematic review and meta-analysis. Cardiovasc Drugs Ther 2021:In press Lin X. Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve replacement: a systematic review and meta-analysis. Cardiovasc Drugs Ther 2021:In press
12.
Zurück zum Zitat Dauerman HL, et al. Prolonged clotting time among patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(6):820–1.CrossRefPubMedPubMedCentral Dauerman HL, et al. Prolonged clotting time among patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(6):820–1.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ten Berg J, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J. 2021;42(23):2265–9.CrossRefPubMed Ten Berg J, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J. 2021;42(23):2265–9.CrossRefPubMed
14.
Zurück zum Zitat Writing Committee M, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;77(4):450–500. Writing Committee M, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;77(4):450–500.
Metadaten
Titel
Dual Anti-platelet Therapy After Transcatheter Aortic Valve Implantation: Double Trouble?
verfasst von
Faisal Rahman
Waleed T. Kayani
Yochai Birnbaum
Hani Jneid
Publikationsdatum
22.11.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2022
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07296-7

Weitere Artikel der Ausgabe 6/2022

Cardiovascular Drugs and Therapy 6/2022 Zur Ausgabe

So beeinflussen Herzinfarkte auf lange Sicht die Sterblichkeit

20.06.2024 ST-Hebungsinfarkt Nachrichten

Wie hoch ist bei Patienten, die nach einem ST-Hebungs-Myokardinfarkt die initiale Hochrisikophase überleben, auf lange Sicht das Sterberisiko? Eine Studie aus Dänemark liefert dazu nun aufschlussreiche Daten.

Protonenpumpenhemmer stoppt Arrhythmie

20.06.2024 Protonenpumpenhemmstoffe Nachrichten

Wenn Nervenfasern aus dem Magen und dem Herzen im Gehirn dicht beieinander liegen, kann auch mal etwas schiefgehen: So lässt sich erklären, weshalb Schmerzen durch einen Magentumor bei einem Mann eine ventrikuläre Extrasystolie auslösen – und PPI diese beenden.

Ob Apixaban nützt oder schadet, entscheidet der CHA2DS2-VASc-Score

20.06.2024 Therapie des Vorhofflimmerns Nachrichten

Patienten mit subklinischem Vorhofflimmern tragen ein erhöhtes Risiko für Schlaganfälle. Da stellt sich die Frage nach einer medikamentösen Antikoagulation. Offenbar hängt es aber vom CHA2DS2-VASc-Score ab, ob die Gabe von Apixaban von Vorteil ist.

Wie SGLT2-Hemmer es schaffen, die Mortalität zu reduzieren

20.06.2024 Kardiologische Therapie Nachrichten

SGLT2-Hemmer verhindern keine Herzinfarkte oder Schlaganfälle. Aber sie reduzieren die kardiovaskuläre Mortalität bei einem breiten Spektrum von Patienten. Wie sie das schaffen, verdeutlicht eine Metaanalyse von Daten aus elf randomisierten Studien.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.